Literature DB >> 9445850

[Principle requirements for an electromechanical transducer for implantable hearing aids in inner ear hearing loss. I: Technical and audiologic aspects].

H Leysieffer1.   

Abstract

In order to overcome the disadvantages of hearing aids, a significant amount of research aimed at replacing them by implanted ossicular-coupled electronic hearing devices is being carried out. The technical and audiological demands on the electromechanical transducer of an implantable hearing aid for moderate to severe sensorineural hearing losses include high transmission quality of the equivalent sound-pressure level without significant linear or nonlinear distortion, and an energy balance suitable for implantation. Fundamental specifications for a transducer are a high spectral bandwidth of up to 10 kHz, an elongation amplitude of at least 100 nm within this range, a small ripple of the elongation frequence response of around +/- 3 dB, a total harmonic distortion (THD) of less than 0.5%, and a maximum electric power consumption of 0.1 mW. The demands on construction, such as hermetic sealing, biocompatibility, and biostability, are also discussed in detail. It appears that optimum transducer design is essentially a compromise between the physical requirements which are in part conflicting regardless of the transducer principle employed.

Entities:  

Mesh:

Year:  1997        PMID: 9445850     DOI: 10.1007/s001060050156

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  2 in total

1.  Investigation of a novel completely-in-the-canal direct-drive hearing device: a temporal bone study.

Authors:  Hossein Mahboubi; Peyton Paulick; Saman Kiumehr; Mark Merlo; Mark Bachman; Hamid Reza Djalilian
Journal:  Otol Neurotol       Date:  2013-01       Impact factor: 2.311

Review 2.  [Differential indication of active middle ear implants].

Authors:  K Braun; H-P Zenner; N Friese; A Tropitzsch
Journal:  HNO       Date:  2015-06       Impact factor: 1.284

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.